BiotechTube

MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningococcal Disease

Conditions

Meningococcal Disease, Meningococcal Meningitis

Trial Timeline

Sep 1, 2011 → Nov 1, 2012

NCT ID
NCT01434680

About MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV

MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV is a phase 2 stage product being developed by Novartis for Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01434680. Target conditions include Meningococcal Disease, Meningococcal Meningitis.

What happened to similar drugs?

10 of 20 similar drugs in Meningococcal Disease were approved

Approved (10) Terminated (0) Active (10)
✅Meningococcal C conjugate vaccineNovartisApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccineNovartisApproved
✅Meningococcal C conjugate vaccineNovartisApproved
✅TrumenbaPfizerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01434680Phase 2Completed

Competing Products

20 competing products in Meningococcal Disease

See all competitors
ProductCompanyStageHype Score
RotaTeq® + NeisVac-C®MerckPhase 3
40
Meningococcal C conjugate vaccineNovartisApproved
43
Meningococcal (group B) multicomponent recombinant adsorbed vaccine. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)NovartisPhase 2
35
Meningococcal ACWY-CRM conjugate vaccine + Meningococcal ACWY-PS polysaccharide vaccineNovartisPhase 3
40
1a - rMenB+OMV NZ and routine vaccines + 1b - rMenB+OMV NZ and routine vaccines + 2a - Routine and rMenB+OMV NZ vaccines + 2b - rMenB+OMV NZ and routine vaccines + 3a - rMenB+OMV NZ and routine vaccines + 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations + 4a- rMenB+OMV NZ and routine vaccines + 4b - rMenB+OMV NZ and routine vaccinesNovartisPhase 3
40
MenACWY-CRMNovartisPre-clinical
26
Meningococcal C conjugate vaccineNovartisApproved
43
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
43
rMenB + rMenB+OMV NZNovartisPhase 2
35
Typhoid Vi Polysaccharide Vaccine + Yellow Fever Vaccine + Japanese Encephalitis Vaccine + Rabies Vaccine + MenACWY-CRM VaccineNovartisPhase 3
40
rMenB+OMV NZNovartisPhase 3
40
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
40
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + TdapNovartisPhase 2
35
MenACWY-CRMNovartisPhase 3
40
rMenB + rMenB+OMVNovartisPhase 2
35
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.NovartisPhase 2
35
MenABCWY+OMV + MenABCWY+¼OMV + PlaceboNovartisPhase 2
35
Novartis MenACWY-CRM + Saline PlaceboNovartisPhase 3
40
rMenB+OMV NZ + PlaceboNovartisPhase 2/3
38
rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccineNovartisPhase 3
40